ERBB2 and neoplasm: In our previous paper, we discussed that pan-HER targeting might decrease tumor resistance to EGFR targeted therapy [12] because, as mentioned above, EGFR receptors show crosstalk with HER2, which plays key roles in resistance in Tras-R cells [110].